Precision Medicine Personalized Treatment Plans: What Leading Physicians Say Works in 2026
Introduction: The Promise and the Gap in Precision Medicine Today
The global precision medicine market stands at approximately $119–157 billion in 2025, representing one of healthcare’s most rapidly expanding frontiers. Yet beneath these impressive figures lies a troubling clinical reality: only 36% of non-small cell lung cancer patients receive the medication their biomarker tests indicate they need. This testing-to-treatment gap reveals that the science of precision medicine has outpaced its clinical implementation—and practicing physicians are navigating this disconnect daily at the point of care.
This examination moves beyond explaining what precision medicine is. Instead, it offers a physician-voice-forward exploration of how personalized treatment plans are actually built, implemented, and sometimes fail to reach the patients who need them most. The focus extends beyond oncology’s well-documented advances into precision psychiatry, rare disease treatment, and metabolic disorders—specialties where groundbreaking work receives insufficient mainstream attention.
Understanding how leading physicians translate genomic insights into individualized care plans has never been more relevant for patients seeking to make informed healthcare decisions and for clinicians working to deliver on precision medicine’s promise.
How Physicians Actually Build a Personalized Treatment Plan: The Clinical Reality
Constructing a personalized treatment plan involves far more than ordering a genetic test. Physicians follow a complex workflow that begins with comprehensive patient history review and extends through biomarker testing, genomic sequencing interpretation, multi-disciplinary team consultation, and ultimately therapy selection.
Next-generation sequencing (NGS) serves as a foundational tool in this process, holding over 35% of global precision medicine market share in 2025. Through NGS, physicians identify actionable mutations—genetic alterations that indicate a patient may respond to specific targeted therapies. The technology enables clinicians to move from broad-spectrum treatments toward interventions designed for an individual’s specific disease biology.
Pharmacogenomics represents the largest technology segment at 30.2% market share. These genetic tests reveal how an individual’s DNA affects drug metabolism, allowing physicians to select medications and dosages tailored to each patient. A medication that works well for one patient may be ineffective or cause severe side effects in another due to genetic variations in drug-processing enzymes.
The complexity of interpreting this data cannot be overstated. Approximately 46% of physicians report needing additional training to interpret personalized treatment data effectively. This knowledge gap underscores why building a personalized treatment plan remains an iterative process rather than a single event. Physicians adjust therapies based on patient response, new biomarker data, and evolving clinical evidence—continuously refining the approach as more information becomes available.
Emerging tools are beginning to help. Multi-modal AI integration—combining genomics, medical imaging, and electronic health record data—represents the next frontier in clinical decision support, offering physicians sophisticated analysis that would be impossible to derive manually at scale.
The Testing-to-Treatment Gap: Why Biomarker Results Don’t Always Lead to Better Care
The testing-to-treatment gap describes a clinical phenomenon that frustrates physicians and harms patients: individuals receive biomarker or genomic testing but still do not receive the targeted therapy their results indicate. This gap persists even in precision oncology, the most advanced and well-resourced area of personalized medicine.
Research published in JCO Precision Oncology quantified this problem starkly, showing that 147 of 503 NSCLC patients were lost at a single practice gap step—meaning they fell through the cracks somewhere between diagnosis and optimal treatment. When only 36% of lung cancer patients receive the right medication despite available testing, the gap becomes a matter of life and death.
Physicians identify several structural causes: fragmented electronic health record systems that fail to communicate critical results, delays in pathology reporting, lack of standardized biomarker testing protocols across health systems, insufficient specialist referral pathways, and insurance reimbursement barriers that delay or deny coverage for indicated therapies.
The problem extends beyond individual practices. Approximately 37% of organizations struggle to scale pilot precision medicine programs into full clinical deployment, indicating systemic rather than isolated failures.
The smart precision medicine software market—growing from $2.89 billion in 2024 to a projected $6.55 billion by 2029—is being developed specifically to address these challenges through better data integration and clinical decision support tools that ensure test results translate into treatment action.
Precision Medicine Beyond Oncology: What Physicians Are Doing in Underserved Specialties
While oncology dominates precision medicine coverage, physicians in other specialties are advancing personalized treatment in ways that deserve greater attention.
Precision Psychiatry: Matching Mental Health Treatment to Biology
Precision psychiatry uses pharmacogenomic testing to guide antidepressant, antipsychotic, and mood stabilizer selection—addressing the longstanding trial-and-error approach that has characterized psychiatric medication management for decades.
The NIH All of Us program has demonstrated the scale of this opportunity: as of early 2026, 145,000 participants have received actionable pharmacogenomic information affecting at least one medication, with mental health medications among the most commonly implicated drug classes.
Psychiatrists now use genetic markers to predict which patients are rapid or poor metabolizers of SSRIs and other psychiatric medications. This information reduces adverse events and improves treatment adherence by matching patients with medications their bodies can process effectively. Understanding the relationship between serotonin and depression is one area where this genomic insight is proving particularly valuable for clinicians.
AI-driven pharmacogenomics research shows that clinicians can classify patients and select medications based on DNA profiles, reducing side effects and increasing therapeutic efficacy in neurological and psychiatric conditions. However, the physician training gap remains particularly acute in psychiatry, where genomic literacy is less established than in oncology.
Rare Disease: When Personalization Is the Only Option
This milestone illustrates how rare disease physicians build treatment plans from scratch using whole genome sequencing, functional genomics, and in some cases custom-designed therapies. The FDA approved 16 new personalized treatments for rare diseases in 2023, up from 6 in 2022, reflecting accelerating regulatory momentum that physicians are now navigating in clinical practice.
The global cell and gene therapy market is projected to grow from $25 billion in 2025 to approximately $117 billion by 2034, signaling the pipeline of treatments rare disease physicians will be implementing. These clinicians face unique emotional and logistical complexity when a patient’s treatment plan is truly one-of-a-kind, requiring them to communicate both uncertainty and hope to families. Stem cell research continues to intersect with these rare disease treatment advances, expanding the toolkit available to specialists.
Metabolic Disorders: CRISPR and Genomics Enter Cardiology and Endocrinology
Cardiologists and endocrinologists are beginning to use genomic profiling to identify patients with familial hypercholesterolemia, PCSK9 variants, and other hereditary metabolic conditions who are candidates for precision therapies. Pharmacogenomics is also changing diabetes and obesity management, with physicians using genetic data to select GLP-1 agonists, metformin, and other agents based on predicted individual response.
Multi-omics integration—combining genomics with metabolomics and proteomics—is particularly relevant to metabolic disorders, where gene expression, protein function, and metabolite levels all interact to drive disease. Metabolic precision medicine remains earlier in its clinical implementation curve than oncology, and physicians emphasize that expanded training and infrastructure are needed to accelerate adoption.
The Role of AI in Translating Genomic Data Into Clinical Decisions
In 2026, AI models analyze patient genomics, history, and treatment data to recommend optimal therapies or clinical trial participation. SOPHiA GENETICS’ AI-driven platform analyzed over two million patient genomes in 2025, being deployed across healthcare centers worldwide to accelerate turnaround times and improve diagnostic accuracy.
The AI-in-precision-medicine market trajectory reflects this momentum: projected growth from $3.97 billion in 2026 to $125.81 billion by 2040 at a CAGR of 28%—the fastest-growing segment within the field.
Yet physicians express legitimate concerns about AI in clinical decision-making. Questions of explainability persist: clinicians need to understand why an algorithm recommends a particular therapy, not simply accept its output. Liability questions remain unresolved when AI contributes to treatment decisions. The risk of over-reliance on algorithmic recommendations without sufficient clinical judgment also represents a real concern.
The Illumina–Cleveland Clinic partnership to create a cloud-based platform integrating genomic data into everyday patient care exemplifies the infrastructure being built to support AI-assisted precision medicine in clinical workflows.
The Equity Problem: Who Gets Access to Personalized Treatment Plans
Research examining precision medicine’s reliance on advanced technologies highlights that underrepresentation of diverse populations in genetic research leads to measurable differences in treatment outcomes. The NAACP’s 75-page report released in late 2025 called for equity-first standards in health AI, including bias audits and community governance councils.
Structural access barriers compound the problem: high costs of advanced diagnostics and gene therapies, inconsistent insurance reimbursement, data fragmentation, and workforce shortages particularly affect underserved communities.
India’s February 2026 government initiative to integrate genomics research and precision diagnostics into the national healthcare system offers a model for expanding access in emerging markets. Leading physicians emphasize that delivering equitable precision medicine requires diverse biobank participation, community health worker integration, and payer policy reform.
What Physicians Say Needs to Change: Closing the Implementation Gap
Physicians closest to the point of care identify consistent systemic barriers: training deficits, data fragmentation, equity gaps, and reimbursement inconsistencies. Addressing these requires structural solutions.
The physician training gap demands attention from medical education institutions and professional associations. Multi-disciplinary tumor boards and precision medicine committees serve as clinical infrastructure that helps individual physicians navigate complex genomic data—a model that should expand beyond oncology.
US government funding cuts in 2025, including proposed 40% NIH budget reductions, represent a significant headwind for precision medicine research and development. These cuts may slow CRISPR and genomics research pipelines and shift clinical trial activity to other countries—a development with direct implications for US patient access.
The Patient’s Role in Their Own Personalized Treatment Plan
Physicians increasingly involve patients as active participants in building their treatment plans—sharing genomic results, explaining biomarker implications, and incorporating patient preferences into therapy selection.
The NIH All of Us Research Program has grown to over 873,000 consented participants, with 5,500 having received results with direct health implications such as cancer risk or risk of sudden death. Wearable health technology and real-time continuous monitoring are becoming components of personalized treatment plans, providing physicians with longitudinal data between clinical visits.
Informed patients who ask for biomarker testing and targeted therapies are influencing clinical practice, and patient advocacy continues to drive access improvements across the healthcare system. Patients who also focus on eating healthy and maintaining strong lifestyle habits can further support the effectiveness of their personalized treatment protocols.
Conclusion: Precision Medicine’s Clinical Future Depends on Closing the Gap Between Discovery and Delivery
The science of precision medicine has never been more advanced—from personalized CRISPR therapies at Children’s Hospital of Philadelphia to AI platforms analyzing millions of genomes. Yet the clinical implementation gap remains the defining challenge of 2026.
Physicians identify the same systemic barriers across specialties: training deficits, data fragmentation, equity gaps, and reimbursement inconsistencies. Addressing these requires coordinated action from healthcare systems, payers, educators, and policymakers.
The momentum is undeniable: a global market growing toward $237–537 billion, AI tools advancing at a 28% CAGR, and landmark therapies reaching patients who previously had no options. For patients like KJ at CHOP, or the 64% of NSCLC patients still not receiving the right medication, closing the testing-to-treatment gap is not an abstract policy goal—it is a matter of survival and quality of life.
Take the Next Step: Connect With a Physician Who Specializes in Personalized Medicine
Patients seeking personalized treatment approaches should ask their current physicians about biomarker testing and pharmacogenomic screening as starting points for more individualized care. Healthcare professionals can explore emerging precision medicine tools, clinical implementation strategies, and physician education resources to advance their practice.
Top Doctor Magazine continues covering precision medicine breakthroughs, physician perspectives, and patient-centered health innovation. Physicians specializing in precision medicine, pharmacogenomics, rare disease, or precision psychiatry who wish to share their expertise and clinical insights are encouraged to connect for potential editorial features, interviews, or award nominations—contributing to the essential work of bridging clinical expertise and patient understanding.
